 MELBOURNE, Australia, Jan. 21, 2021 GLOBE NEWSWIRE -- Genetic Technologies Limited ASX: GTG; NASDAQ: GENE the Company, a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,250,000 American Depositary Shares ADSs, each representing six hundred 600 of the Companys ordinary shares, at a purchase price of 5.25 per ADS. The closing of the offering is expected to occur on or about January 25, 2021, subject to the satisfaction of customary closing conditions. 